La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Pharmaniaga Berhad Croissance future

Future contrôle des critères 3/6

Pharmaniaga Berhad devrait augmenter ses bénéfices et ses revenus de 115.2% et de 1.9% par an respectivement, tandis que le BPA devrait croître de croître de 115.6% par an.

Informations clés

115.2%

Taux de croissance des bénéfices

115.6%

Taux de croissance du BPA

Healthcare croissance des bénéfices	2.4%
Taux de croissance des recettes	1.9%
Rendement futur des capitaux propres	n/a
Couverture par les analystes	Low
Dernière mise à jour	23 Aug 2024

Mises à jour récentes de la croissance future

Recent updates

Pharmaniaga Berhad's (KLSE:PHARMA) Shares Bounce 25% But Its Business Still Trails The Industry

Jul 18

Why Investors Shouldn't Be Surprised By Pharmaniaga Berhad's (KLSE:PHARMA) Low P/S

May 09

Pharmaniaga Berhad (KLSE:PHARMA) Shares Could Be 49% Below Their Intrinsic Value Estimate

Apr 19

Insufficient Growth At Pharmaniaga Berhad (KLSE:PHARMA) Hampers Share Price

Oct 03

Is There An Opportunity With Pharmaniaga Berhad's (KLSE:PHARMA) 37% Undervaluation?

Jul 19

Is It Too Late To Consider Buying Pharmaniaga Berhad (KLSE:PHARMA)?

Feb 18

Many Would Be Envious Of Pharmaniaga Berhad's (KLSE:PHARMA) Excellent Returns On Capital

Dec 10

Bullish: Analysts Just Made A Massive Upgrade To Their Pharmaniaga Berhad (KLSE:PHARMA) Forecasts

Nov 24

We Think That There Are Issues Underlying Pharmaniaga Berhad's (KLSE:PHARMA) Earnings

Aug 27

Pharmaniaga Berhad (KLSE:PHARMA) Has A Somewhat Strained Balance Sheet

May 28

Prévisions de croissance des bénéfices et des revenus

KLSE:PHARMA - Estimations futures des analystes et données financières antérieures (MYR Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2025	3,577	49	35	95	1
12/31/2024	3,507	51	29	89	1
6/30/2024	3,479	-56	-121	-60	N/A
3/31/2024	3,489	-57	-7	57	N/A
12/31/2023	3,404	-80	-14	47	N/A
9/30/2023	3,507	-667	-76	-15	N/A
6/30/2023	3,487	-654	-22	37	N/A
3/31/2023	3,399	-655	-278	-218	N/A
12/31/2022	3,481	-630	-220	-142	N/A
9/30/2022	3,330	100	-186	-105	N/A
6/30/2022	4,568	164	145	214	N/A
3/31/2022	4,984	177	-24	32	N/A
12/31/2021	4,815	172	-109	-64	N/A
9/30/2021	4,738	80	-2	37	N/A
6/30/2021	3,230	32	-394	-356	N/A
3/31/2021	2,699	28	-69	-30	N/A
12/31/2020	2,725	27	-58	-26	N/A
9/30/2020	2,806	-145	0	44	N/A
6/30/2020	2,898	-146	48	111	N/A
3/31/2020	2,854	-146	-21	46	N/A
12/31/2019	2,821	-149	117	190	N/A
9/30/2019	2,701	34	108	176	N/A
6/30/2019	2,572	48	33	106	N/A
3/31/2019	2,553	44	100	181	N/A
12/31/2018	2,385	42	-154	-82	N/A
9/30/2018	2,402	60	-122	-42	N/A
6/30/2018	2,388	48	-80	-20	N/A
3/31/2018	2,324	52	N/A	-12	N/A
12/31/2017	2,324	54	N/A	239	N/A
9/30/2017	2,294	31	N/A	209	N/A
6/30/2017	2,234	41	N/A	231	N/A
3/31/2017	2,248	46	N/A	218	N/A
12/31/2016	2,189	46	N/A	35	N/A
9/30/2016	2,286	62	N/A	50	N/A
6/30/2016	2,296	69	N/A	54	N/A
3/31/2016	2,277	71	N/A	1	N/A
12/31/2015	2,189	84	N/A	7	N/A
9/30/2015	2,136	105	N/A	17	N/A
6/30/2015	2,114	100	N/A	52	N/A
3/31/2015	2,126	99	N/A	95	N/A
12/31/2014	2,123	94	N/A	213	N/A
9/30/2014	2,064	78	N/A	170	N/A
6/30/2014	2,002	67	N/A	140	N/A
3/31/2014	1,915	57	N/A	206	N/A
12/31/2013	1,947	55	N/A	255	N/A
9/30/2013	1,861	26	N/A	161	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: PHARMA devrait devenir rentable au cours des 3 prochaines années, ce qui est considéré comme une croissance plus rapide que le taux d'épargne ( 3.6% ).

Bénéfices vs marché: PHARMA devrait devenir rentable au cours des 3 prochaines années, ce qui est considéré comme une croissance supérieure à la moyenne du marché.

Croissance élevée des bénéfices: PHARMA devrait devenir rentable dans les 3 prochaines années.

Chiffre d'affaires vs marché: Le chiffre d'affaires de PHARMA ( 1.5% par an) devrait croître plus lentement que le marché de MY ( 6.3% par an).

Croissance élevée des revenus: Le chiffre d'affaires de PHARMA ( 1.5% par an) devrait croître plus lentement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de PHARMA devrait être élevé dans 3 ans

Pharmaniaga Berhad Croissance future

Future contrôle des critères 3/6

Informations clés

Mises à jour récentes de la croissance future

Price target decreased by 19% to RM0.28

Price target decreased by 33% to RM0.41

Consensus EPS estimates fall by 13%

Price target decreased to RM0.75

Price target decreased to RM0.87

Consensus EPS estimates increase to RM0.09

Recent updates

Pharmaniaga Berhad Announces Redesignation of Encik Zulkifli Bin Jafar from Executive Director to Managing Director, Effective September 1, 2024

Second quarter 2024 earnings released

High number of new directors

New minor risk - Share price stability

Pharmaniaga Berhad's (KLSE:PHARMA) Shares Bounce 25% But Its Business Still Trails The Industry

Now 20% overvalued after recent price rise

First quarter 2024 earnings released: EPS: RM0.018 (vs RM0.002 in 1Q 2023)

Now 24% undervalued after recent price drop

Why Investors Shouldn't Be Surprised By Pharmaniaga Berhad's (KLSE:PHARMA) Low P/S

Pharmaniaga Berhad, Annual General Meeting, Jun 05, 2024

High number of new directors

Pharmaniaga Berhad Appoints Tuan Drs. Imam Fathorrahman as Independent and Non Executive Member of Audit Committee

Pharmaniaga Berhad Announces the Retirement of Encik Mohamed Iqbal Abdul Rahman as Chief Operating Officer

New major risk - Revenue and earnings growth

Full year 2023 earnings released: RM0.057 loss per share (vs RM0.46 loss in FY 2022)

Pharmaniaga Berhad Appoints Tuan Drs. Imam Fathorrahman as Independent and Non Executive Director, Effective March 1, 2024

Pharmaniaga Berhad Appoints Dato' Dr Faridah Aryani Binti Md Yusof, as Independent and Non Executive Director Effective March 1, 2024

Pharmaniaga Berhad Announces Resignation of Puan Dayana Rogayah Binti Omar as Non Independent and Non Executive Alternate Director

New minor risk - Share price stability

Third quarter 2023 earnings released: RM0.037 loss per share (vs RM0.007 profit in 3Q 2022)

Price target decreased by 19% to RM0.28

High number of new and inexperienced directors

Second quarter 2023 earnings released: EPS: RM0.002 (vs RM0.001 in 2Q 2022)

Pharmaniaga Berhad Announces Appointment of Encik Ahmad Shahredzuan Mohd Shariff as Non Independent and Non Executive Member of Risk Committee

New minor risk - Shareholder dilution

New minor risk - Market cap size

Pharmaniaga Berhad announced that it expects to receive MYR 44.20988 million in funding

Pharmaniaga Berhad Announces the Retirement of Dr Mary Jane Cardosa as Independent and Non Executive Member of Risk Committee

First quarter 2023 earnings released: EPS: RM0.002 (vs RM0.021 in 1Q 2022)

Pharmaniaga Berhad Announces the Resignation of Datuk Dr Azhar Ahmad as Independent and Non Executive Director

Pharmaniaga Berhad (KLSE:PHARMA) Shares Could Be 49% Below Their Intrinsic Value Estimate

Full year 2022 earnings released: RM0.46 loss per share (vs RM0.13 profit in FY 2021)

Price target decreased by 33% to RM0.41

Pharmaniaga Berhad Announces Resignation of Najmil Faiz Mohamed Aris as Independent and Non Executive Member of Nomination and Remuneration Committee

Third quarter 2022 earnings released: EPS: RM0.007 (vs RM0.038 in 3Q 2021)

Pharmaniaga Berhad Declares Third Interim Dividend for the Third Quarter Ended 30 September 2022, payable on 22 February 2023

High number of new directors

Pharmaniaga Berhad (KLSE:PHARMA) entered into a Memorandum of Understanding to acquire JDMAS Commerce Sdn Bhd.

Insufficient Growth At Pharmaniaga Berhad (KLSE:PHARMA) Hampers Share Price

Consensus EPS estimates fall by 13%

Price target decreased to RM0.75

Second quarter 2022 earnings released: EPS: RM0.001 (vs RM0.01 in 2Q 2021)

Pharmaniaga Berhad Announces Second Interim Dividend for the Year Ended December 31, 2022, Payable on October 04, 2022

Pharmaniaga Berhad Appoints Mary Jane Cardosa as Independent and Non Executive Member of Risk Committee

Pharmaniaga Berhad Appoints Mary Jane Cardosa as Independent and Non Executive Director

Pharmaniaga Berhad Appoints Datuk Lim Thean Shiang as Independent and Non Executive Director

Is There An Opportunity With Pharmaniaga Berhad's (KLSE:PHARMA) 37% Undervaluation?

Price target decreased to RM0.87

Pharmaniaga Berhad Declares First Interim Dividend for the Financial Year Ending 31 December 2022, Payable on 06 July 2022

Pharmaniaga Berhad Appoints Abdul Razak Bin Ahmad as Independent and Non-Executive Member of Risk Committee

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Pharmaniaga Berhad, Annual General Meeting, Jun 13, 2022

High number of new and inexperienced directors

Upcoming dividend of RM0.05 per share

Is It Too Late To Consider Buying Pharmaniaga Berhad (KLSE:PHARMA)?

Pharmaniaga Berhad Declares Fourth Interim Dividend for the Financial Year Ending 31 December 2021, Payable on 05 April 2022

Full year 2021 earnings: EPS and revenues miss analyst expectations

Pharmaniaga Berhad Announces Re-Designation of Encik Zulkifli Jafar, Independent Director as Executive Director

Many Would Be Envious Of Pharmaniaga Berhad's (KLSE:PHARMA) Excellent Returns On Capital

Consensus EPS estimates increase to RM0.09

Upcoming dividend of RM0.02 per share

Bullish: Analysts Just Made A Massive Upgrade To Their Pharmaniaga Berhad (KLSE:PHARMA) Forecasts

Third quarter 2021 earnings released: EPS RM0.038 (vs RM0.001 in 3Q 2020)

Upcoming dividend of RM0.015 per share

We Think That There Are Issues Underlying Pharmaniaga Berhad's (KLSE:PHARMA) Earnings

Independent Non-Executive Director Zainal Shariff has left the company

Second quarter 2021 earnings released: EPS RM0.011 (vs RM0.008 in 2Q 2020)

Pharmaniaga Berhad (KLSE:PHARMA) Has A Somewhat Strained Balance Sheet

Investor sentiment improved over the past week